依鲁替尼耐药机制的研究进展

Progress of drug resistance mechanism of ibrutinib

依鲁替尼作为一种新型分子靶向抗肿瘤药物,其被证实有强大的抗肿瘤活性,且具有高效低毒的特点.尽管如此,其相关的耐药性、安全性、疾病类型转化风险也逐步受到关注.文章就近年来依鲁替尼在多种B细胞性非霍奇金淋巴瘤中耐药机制的研究进展作一综述.

As a novel molecular targeted anti-tumor drug,it has been proved that ibrutinib has remarkable anti-tumor activity and is characterized by high efficiency and low toxicity.However,the risks of drug resistance,safety,and disease transformation are gradually concerned.This review focused on the research progress of ibrutinib's drug resistance mechanism in various B-cell non-Hodgkin lymphomas.